tiprankstipranks
Advertisement
Advertisement

ZNTL Stock Latest News

Advancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
RatingsAdvancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
12d ago
ZNTL
ZNTL Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ZNTL Earnings this Week: How Will it Perform?
1M ago
ZNTL
Zentalis outlines 2026 milestones for azenosertib program
PremiumCompany Announcements
Zentalis outlines 2026 milestones for azenosertib program
3M ago
8K
ZNTL
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
PremiumRatings
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
3M ago
ZNTL
Zentalis provides update, key milestones in 2025, expectations for 2026
PremiumThe Fly
Zentalis provides update, key milestones in 2025, expectations for 2026
3M ago
ZNTL
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
PremiumCompany AnnouncementsZentalis Pharmaceuticals Announces Stock Repurchase Agreement
4M ago
8K
ZNTL
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
Premium
Company Announcements
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
5M ago
ZNTL
Zentalis price target lowered to $4 from $8 at Morgan Stanley
Premium
The Fly
Zentalis price target lowered to $4 from $8 at Morgan Stanley
5M ago
ZNTL
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
PremiumRatings
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
5M ago
ZNTL
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
5M ago
8K
ZNTL
Zentalis reports Q3 EPS (37c), consensus (48c)
PremiumThe Fly
Zentalis reports Q3 EPS (37c), consensus (48c)
5M ago
ZNTL
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
PremiumRatings
Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals
5M ago
ZNTL
Zentalis board member Letai frontrunner to lead NCI, STAT reports
PremiumThe FlyZentalis board member Letai frontrunner to lead NCI, STAT reports
7M ago
ZNTL
Zentalis Pharmaceuticals Announces New Chief Legal Officer
Premium
Company Announcements
Zentalis Pharmaceuticals Announces New Chief Legal Officer
8M ago
8K
ZNTL
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
Premium
The Fly
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
8M ago
ZNTL
Zentalis price target lowered to $5 from $6 at Wells Fargo
PremiumThe Fly
Zentalis price target lowered to $5 from $6 at Wells Fargo
8M ago
ZNTL
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals
PremiumRatings
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals
8M ago
ZNTL
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism
PremiumRatings
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism
8M ago
ZNTL
Zentalis Pharmaceuticals Reports Improved Financial Results
PremiumCompany Announcements
Zentalis Pharmaceuticals Reports Improved Financial Results
8M ago
ZNTL
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsZentalis Pharmaceuticals Reports Q2 2025 Financial Results
8M ago
8K
ZNTL
Zentalis management to meet with Oppenheimer
Premium
The Fly
Zentalis management to meet with Oppenheimer
9M ago
ZNTL
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting
10M ago
8K
ZNTL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >